NO20054767D0 - Sammensetninger omfattende apomorfin for inhalering i lunge - Google Patents

Sammensetninger omfattende apomorfin for inhalering i lunge

Info

Publication number
NO20054767D0
NO20054767D0 NO20054767A NO20054767A NO20054767D0 NO 20054767 D0 NO20054767 D0 NO 20054767D0 NO 20054767 A NO20054767 A NO 20054767A NO 20054767 A NO20054767 A NO 20054767A NO 20054767 D0 NO20054767 D0 NO 20054767D0
Authority
NO
Norway
Prior art keywords
apomorphine
compositions
lung inhalation
inhalation
lung
Prior art date
Application number
NO20054767A
Other languages
English (en)
Other versions
NO20054767L (no
Inventor
John Nicholas Staniforth
David Morton
Michael Tobyn
Stephen Eason
Quentin Harmer
David Ganderton
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/413,022 external-priority patent/US20040204439A1/en
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of NO20054767D0 publication Critical patent/NO20054767D0/no
Publication of NO20054767L publication Critical patent/NO20054767L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20054767A 2003-04-14 2005-10-17 Sammensetninger omfattende apomorfin for inhalering i lunge NO20054767L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/413,022 US20040204439A1 (en) 2003-04-14 2003-04-14 Composition, device, and method for treating sexual dysfunction via inhalation
US10/621,964 US20040204440A1 (en) 2003-04-14 2003-07-17 Composition, device, and method for treating sexual dysfunction via inhalation
PCT/GB2004/001627 WO2004089374A1 (en) 2003-04-14 2004-04-14 Pharmaceutical compositions comprising apomorphine for pulmonary inhalation

Publications (2)

Publication Number Publication Date
NO20054767D0 true NO20054767D0 (no) 2005-10-17
NO20054767L NO20054767L (no) 2005-12-21

Family

ID=33161980

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054767A NO20054767L (no) 2003-04-14 2005-10-17 Sammensetninger omfattende apomorfin for inhalering i lunge

Country Status (9)

Country Link
US (1) US20060178394A1 (no)
EP (1) EP1613323A1 (no)
JP (1) JP2006522785A (no)
AU (1) AU2004228757A1 (no)
BR (1) BRPI0409380A (no)
CA (1) CA2522231A1 (no)
NO (1) NO20054767L (no)
RU (1) RU2364400C2 (no)
WO (1) WO2004089374A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
WO2006103417A1 (en) * 2005-03-28 2006-10-05 Orexo Ab New pharmaceutical compositions useful in the treatment of parkinson's disease
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
CA2759041A1 (en) * 2009-04-24 2010-10-28 Schering Corporation Agglomerate formulations useful in dry powder inhalers
TW201304822A (zh) * 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
US20160374958A1 (en) * 2015-06-23 2016-12-29 Axim Biotechnologies, Inc. Anti-microbial composition comprising cannabinoids
US11224594B2 (en) 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
US20170071248A1 (en) * 2015-09-16 2017-03-16 Sansa Corporation (Barbados) Inc. System and Method for Controlling the Harshness of Nicotine-Based Dry Powder Formulations
CA3028604C (en) 2016-07-08 2023-12-05 Trudell Medical International Smart oscillating positive expiratory pressure device
ES2920151T3 (es) 2016-12-09 2022-08-01 Trudell Medical Int Nebulizador inteligente
EP3735287A4 (en) 2018-01-04 2021-09-15 Trudell Medical International INTELLIGENT POSITIVE OSCILLATING EXPIRATORY PRESSURE DEVICE
US11712175B2 (en) 2019-08-27 2023-08-01 Trudell Medical International Smart oscillating positive expiratory pressure device with feedback indicia
GB201912686D0 (en) * 2019-09-04 2019-10-16 Reown Pharma Inc Pharmaceutical composition

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080456A (en) * 1971-10-26 1978-03-21 Schering Aktiengesellschaft Diacylapomorphines
US4687773A (en) * 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US5292520A (en) * 1990-09-13 1994-03-08 Akzo N.V. Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
ES2194867T3 (es) * 1993-03-26 2003-12-01 Franciscus Wilhelmus He Merkus Composiciones farmaceuticas para la administracion intranasal de apomorfina.
US6395744B1 (en) * 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US20020165122A1 (en) * 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
KR100374924B1 (ko) * 1994-04-22 2003-07-22 퀸스 유니버시티 엣 킹스톤 남성발기기능장애를회복시키고진단하기위한설하용량형
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US5699789A (en) * 1996-03-11 1997-12-23 Hendricks; Mark R. Dry powder inhaler
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
JP4754067B2 (ja) * 1997-12-02 2011-08-24 アルキメデス ディヴェロプメント リミテッド 鼻孔投与用組成物
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
US6403605B1 (en) * 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
US20020002175A1 (en) * 2000-09-19 2002-01-03 Charanjit Behl Nasal delivery of apomorphine in combination with glycol derivatives
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
GB9827145D0 (en) * 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US7074388B2 (en) * 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
EP1180021A4 (en) * 1999-05-06 2005-01-19 Pentech Pharmaceuticals Inc TREATMENT OF THE PREMATURE EJACULATION AND ASSOCIATED KIT
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
JP2001072586A (ja) * 1999-09-06 2001-03-21 Nikken Chem Co Ltd 吸入用粉末製剤及びその製造方法
JP2001151673A (ja) * 1999-09-06 2001-06-05 Nikken Chem Co Ltd 吸入用粉末製剤の製造方法
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
JP2003532640A (ja) * 2000-04-07 2003-11-05 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド アポモルヒネ誘導体及びその使用方法
US6948494B1 (en) * 2000-05-10 2005-09-27 Innovative Devices, Llc. Medicament container with same side airflow inlet and outlet and method of use
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
CZ20031540A3 (cs) * 2000-11-15 2004-05-12 Tapápharmaceuticaláproductsźáinc Léčivo pro léčení sexuální dysfunkce
US20020086876A1 (en) * 2000-11-15 2002-07-04 Ruff Dustin D. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
JP2002184831A (ja) * 2000-12-11 2002-06-28 Hirata Corp Ｆｏｕｐオープナ
WO2003026631A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
JP2005503425A (ja) * 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation

Also Published As

Publication number Publication date
CA2522231A1 (en) 2004-10-21
US20060178394A1 (en) 2006-08-10
JP2006522785A (ja) 2006-10-05
RU2005135133A (ru) 2006-06-10
BRPI0409380A (pt) 2006-04-18
RU2364400C2 (ru) 2009-08-20
AU2004228757A1 (en) 2004-10-21
EP1613323A1 (en) 2006-01-11
WO2004089374A1 (en) 2004-10-21
NO20054767L (no) 2005-12-21

Similar Documents

Publication Publication Date Title
NO20054767D0 (no) Sammensetninger omfattende apomorfin for inhalering i lunge
LTPA2017028I1 (lt) Fungicidų kompozicijos
CY2014030I1 (el) Θεραπευτικες συνθεσεις που περιλαμβανουν ingenol-3-angelate
BRPI0613033A2 (pt) composição oral
BRPI0719626A2 (pt) '' composto ''
ITMI20041252A1 (it) Composizioni perfluoroelastomeriche
DE602004013496D1 (de) Mikrobizide Zusammensetzung
DE602005020680D1 (de) Mikrobizide Zusammensetzung
ATE453394T1 (de) Multipartikeln
DE602006021644D1 (de) Fungizidzusammensetzungen
DE602005016978D1 (de) Quecksilberfreisetzende Zusammensetzungen
DE602004001461D1 (de) Verstärkte polyoxymethylen-polymilchsäure zusammensetzungen
DK1811995T3 (da) En transmucosal veterinær sammensætning omfattende detomidin
ATE404546T1 (de) Substituierte n-sulfonylaminobenzyl-2- phenoxyacetamidverbindungen
DE602005017191D1 (de) Geruchsreduzierte waschstück-zusammensetzung
DE602004018512D1 (de) Stifte zusammensetzungen
ATE498308T1 (de) Glyphosate-zusammensetzung
DE502004010641D1 (de) Atemschutzmaske
ITBO20050074U1 (it) Manufatto per l'edilizia
NO20043489L (no) Sammensetning for inhalering
ATE465231T1 (de) Stabilisierte propylbromidzusammensetzungen
ATE365529T1 (de) Schweisshemmende zusammensetzungen
NO20042027L (no) Oral composition
DE50306766D1 (de) Schalldämpfende Zusammensetzung
MA28462B1 (fr) Formulations pour inhalation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application